Coherus BioSciences (NASDAQ:CHRS) Issues Earnings Results

Coherus BioSciences (NASDAQ:CHRSGet Rating) issued its earnings results on Thursday. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.17, Fidelity Earnings reports. Coherus BioSciences had a negative return on equity of 211.68% and a negative net margin of 69.24%. During the same quarter in the previous year, the company earned ($0.40) EPS.

Coherus BioSciences Stock Up 11.8 %

NASDAQ CHRS traded up $1.25 during trading on Friday, hitting $11.83. The stock had a trading volume of 1,711,200 shares, compared to its average volume of 983,330. The company has a market capitalization of $915.91 million, a PE ratio of -4.33 and a beta of 1.19. The company’s 50-day moving average price is $7.82 and its two-hundred day moving average price is $10.00. The company has a debt-to-equity ratio of 33.47, a quick ratio of 3.09 and a current ratio of 3.33. Coherus BioSciences has a 12 month low of $5.60 and a 12 month high of $19.32.

Analysts Set New Price Targets

Several research firms have recently weighed in on CHRS. Barclays cut their price objective on Coherus BioSciences from $20.00 to $15.00 in a report on Monday, May 9th. Mizuho cut their price objective on Coherus BioSciences from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, May 20th. UBS Group began coverage on Coherus BioSciences in a report on Monday, June 13th. They set a “neutral” rating and a $7.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Coherus BioSciences in a report on Tuesday, May 3rd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Coherus BioSciences presently has an average rating of “Moderate Buy” and an average target price of $19.00.

Institutional Investors Weigh In On Coherus BioSciences

Institutional investors have recently bought and sold shares of the company. Rhumbline Advisers lifted its stake in Coherus BioSciences by 5.8% in the 1st quarter. Rhumbline Advisers now owns 165,100 shares of the biotechnology company’s stock valued at $2,131,000 after acquiring an additional 8,992 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Coherus BioSciences by 194.1% in the 1st quarter. Renaissance Technologies LLC now owns 164,100 shares of the biotechnology company’s stock valued at $2,119,000 after acquiring an additional 108,300 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Coherus BioSciences by 14.1% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 54,943 shares of the biotechnology company’s stock valued at $709,000 after acquiring an additional 6,775 shares in the last quarter. Ergoteles LLC lifted its stake in Coherus BioSciences by 11.7% in the 1st quarter. Ergoteles LLC now owns 44,704 shares of the biotechnology company’s stock valued at $577,000 after acquiring an additional 4,687 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new stake in Coherus BioSciences in the 1st quarter valued at approximately $455,000. Institutional investors own 97.85% of the company’s stock.

Coherus BioSciences Company Profile

(Get Rating)

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis.

See Also

Earnings History for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.